Dean Bowles Percy1, Emeline J. Ribot1, Catherine McFadden1, Yuhua Chen1, Carmen Simedrea2, Ann F. Chambers2, Patricia S. Steeg3, Paula J. Foster1
1Robarts Research Institute, London, Ontario, Canada; 2London Regional Cancer Program, London, Ontario, Canada; 3National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
Brain metastases are notoriously difficult to treat, in part due to heterogeneity of the blood-brain barrier (BBB) permeability, which can inhibit drug delivery. By using high-resolution 3D bSSFP MRI in tandem with traditional gadolinium-contrast enhanced T1wSE we are the first to longitudinally monitor BBB permeability in breast cancer brain metastases, and by using MR volume measurements, relate this permeability to metastasis size, in vivo. This model can provide the foundation for much needed preclinical evaluation of efficacy and delivery of chemotherapeutics engineered to cross the BBB, and hopefully lead to better clinical management of brain metastases.